Regeneron: Billion-Dollar Deal with Sanofi and New Approvals Secure Market Position
Reading Time: 2 minutes
Revenue climbed in the third quarter to $5.1 billion, driven by sales figures for Dupixent and Eylea HD. A new billion-dollar deal with Sanofi and FDA approval for the drug Pasatru significantly expand the portfolio. Management reports double-digit growth for the third consecutive quarter and sees the long-term orientation intact. Antibody specialist benefits from sustained high demand for immunotherapies The business model of Regeneron (REGN) is based on the research and commercialization of monoclonal antibodies for serious diseases....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
